All these findings form a basis for designing clinical trials investigating anti-HER2 agents in combination with PI3K inhibitors (PI3Ki), to elucidate whether blocking PIK3CA signaling can somehow improve clinical outcomes in HER2+/PIK3CA mutant BC, while better defining the role of PIK3CA mutations in HER2+ BC. This evidence concerns the gene PIK3CD and breast cancer.